Huadong Medicine Co Ltd
SZSE:000963

Watchlist Manager
Huadong Medicine Co Ltd Logo
Huadong Medicine Co Ltd
SZSE:000963
Watchlist
Price: 37.27 CNY 0.32%
Market Cap: 65.4B CNY
Have any thoughts about
Huadong Medicine Co Ltd?
Write Note

Huadong Medicine Co Ltd
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Huadong Medicine Co Ltd
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Huadong Medicine Co Ltd
SZSE:000963
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sinopharm Group Co Ltd
HKEX:1099
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
China National Medicines Corp Ltd
SSE:600511
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
China National Accord Medicines Corp Ltd
SZSE:000028
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Huadong Medicine Co Ltd
Glance View

Market Cap
65.2B CNY
Industry
Health Care

Huadong Medicine Co., Ltd., established in 1995, has emerged as a pivotal player within China's rapidly evolving pharmaceutical landscape. With a robust portfolio that includes innovative cancer treatments, cardiovascular drugs, and biologics, the company focuses on both research and development and the commercialization of high-quality therapeutics. Backed by cutting-edge production facilities and a strong commitment to adhering to international regulatory standards, Huadong not only serves the domestic market but also aspires to extend its reach globally. As the demand for effective healthcare solutions grows, Huadong's strategic alliances and collaborations with research institutions highlight its dedication to staying at the forefront of medical advancements. For investors, Huadong Medicine represents a well-rounded opportunity fueled by a consistent growth trajectory and a commitment to expanding its market presence. The company's focus on high-margin specialty drugs and biologics positions it favorably within the competitive landscape, catering to the increasing prevalence of chronic diseases. With a stable revenue generation model, strong management team, and innovative pipeline, Huadong Medicine is uniquely poised to capture market share and enhance shareholder value in an industry that is increasingly driven by innovation and patient-centric solutions. Investors looking to diversify into the healthcare sector, especially within the growing Asian market, may find Huadong Medicine an attractive addition to their portfolios.

Intrinsic Value
51.07 CNY
Undervaluation 27%
Intrinsic Value
Price

See Also

Back to Top